An issue highlighted by the results of this study is the unclear mechanism through which GALNT14-rs62139523 genotypes influence 5-FU-based adjuvant chemotherapy in stage II and III CRC patients after curative surgery. This evidence concerns the gene GALNT14 and colorectal carcinoma.